Search clinical trials for: UFOX Cetuximab

Total 3068 results

Hoffmann-La Roche

Withdrawn

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab

Colorectal Cancer
Eli Lilly and Company

Completed

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Neoplasms

United States
Dorte Nielsen

Completed

Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma

Cholangiocarcinoma

Denmark
Sun Yat-sen University

Recruiting

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Colorectal Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer
Dragonboat Biopharmaceutical Company Limited
Shanghai East Hospital

Unknown

A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC

Colorectal Cancer

China
Eli Lilly and Company

Completed

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Sanofi; Roche Pharma AG; National...

Completed

Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer (NRR)

Liver Cancer

United States
Quanta Therapeutics

Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Solid Tumors

United States
NSABP Foundation Inc

Withdrawn

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

Colorectal Cancer

United States
Armando Orlandi

Completed

Erbitux MEtastatic Colorectal Cancer Strategy Study

Antineoplastic Agents

Italy
Centre Oscar Lambret

Unknown

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Epidermoid Head and Neck Cancer

France
Regione Lombardia
Mario Negri Institute for Pharmacological Research; Istituto Clinico Humanitas and other collaborators

Completed

Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.

Colorectal Cancer

Italy
Heinrich-Heine University, Duesseldorf

Completed

Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (ACCRA-HN)

Head and Neck Cancer

Germany
Sun Yat-sen University
Zhejiang Cancer Hospital; Wenzhou Medical University; Xijing Hospital; Wuhan University and other collaborators

Completed

Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma (REPLACE)

Nasopharyngeal Carcinoma

China
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Advance Non-small Cell Lung Cancer

Spain, Italy, Greece
Chugai Pharmaceutical

Recruiting

A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Locally Advanced or Metastatic Solid Tumors

United States, Japan
Milton S. Hershey Medical Center

Withdrawn

Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma

Squamous Cell Cancer of the Head and Neck

United States
IntegraGen SA
Federation Francophone de Cancerologie Digestive; Exystat

Completed

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

Colorectal Cancer
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Carcinoma, Squamous Cell

India
Centre Leon Berard

Withdrawn

Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) (PENILANE)

Squamous Cell Carcinoma of the Penis

France
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Massachusetts General Hospital; Beth Israel Deaconess Medical...

Completed

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

Neoplasm Metastasis | Gastric Cancer | Esophageal Cancer

United States
Merck KGaA, Darmstadt, Germany

Withdrawn

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Neoplasms, Squamous Cell
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
ARCAGY/ GINECO GROUP

Terminated

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix (ERBUS)

Cervix Cancer

France
Eli Lilly and Company
Bristol-Myers Squibb

Terminated

A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Ovarian Cancer

United States
M.D. Anderson Cancer Center

Recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Richter Syndrome | Refractory Mantle Cell Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory... and other conditions

United States
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

United States
Harrison Clinical Research
Merck KGaA, Darmstadt, Germany; AstraZeneca

Completed

Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib

Head and Neck Cancer | Colorectal Cancer | Non Small Cell Lung Cancer (NSCLC)

Spain, Belgium
Tang-Du Hospital

Not yet recruiting

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

Rectal Cancer
Northwell Health

Recruiting

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Glioma | Glioblastoma | Brain Cancer | Brain Tumor | Brain Neoplasm | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Brain Tumor, Recurrent | Brain Neoplasm, Malignant

United States
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
Spanish Cooperative Group for the Treatment of...
Roche Pharma AG

Completed

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (VISNU-2)

Colorectal Cancer Metastatic

Spain
Peking University

Unknown

Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Chemotherapy Effect | Esophageal Cancer, Squamous Cell | Cetuximab Effect

China
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Hospices Civils de Lyon

Terminated

Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases

Neoplasm Metastasis | Colorectal Cancer

France
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
Gruppo Italiano per lo studio dei Carcinomi dell...

Completed

Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients (COMETS)

Metastatic Colorectal Cancer

Italy
National Cancer Institute (NCI)

Completed

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (ADCC)

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell... and other conditions

United States
Fudan University

Not yet recruiting

Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

Colorectal Cancer Liver Metastases

China
University of Michigan Rogel Cancer Center

Completed

Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients

HPV | Squamous Cell Carcinoma of the Oropharynx

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Reirradiation and Erbitux in the HNSCC

Head and Neck Cancer Squamous Cell

France
Rambam Health Care Campus
Merck KGaA, Darmstadt, Germany

Completed

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

Colorectal Cancer Metastatic

Israel
Vanderbilt University
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

Gastric Cancer | Precancerous Condition

United States
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype (MUTEX)

Colorectal Neoplasms

Spain
Eli Lilly and Company

Completed

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Advanced Cancer

Puerto Rico, United States
Merck KGaA, Darmstadt, Germany

Completed

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Head and Neck Cancer

Korea, Republic of

Search clinical trials for: UFOX Cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations